Abstract Isocitrate dehydrogenase 1 and 2 (IDH1/2) are key enzymes in cellular metabolism,
epigenetic regulation, redox states, and DNA repair. IDH1/2 mutations are causal in the …

In theory, in vitro and in vivo models for human gliomas have great potential to not only
enhance our understanding of glioma biology, but also to facilitate the development of novel …

Isocitrate dehydrogenase (IDH) is a key rate-limiting enzyme in the Krebs cycle that plays an
important role in energy metabolism. In recent years, it has been found that IDH mutations …

Glioblastoma multiforme (GBM) is a particularly aggressive and malignant type of brain
tumor, notorious for its high recurrence rate and low survival rate. The treatment of GBM is …

Abstract Isocitrate dehydrogenase 1 (IDH1) is mutated in various types of human cancer to
IDH1R132H, a structural alteration that leads to catalysis of α-ketoglutarate to the …

Background: The clinical and prognostic value of programmed death-ligand 1, PD-L1, in
glioblastoma remains controversial. The present study aimed to identify the expression of …

Introduction High-grade chondrosarcoma, high-grade glioma and intrahepatic
cholangiocarcinoma are aggressive types of cancer with a dismal outcome. This is due to …

Hotspot mutations in isocitrate dehydrogenase 1 (IDH1) initiate low-grade glioma and
secondary glioblastoma and induce a neomorphic activity that converts α-ketoglutarate (α …

Simple Summary Isocitrate dehydrogenase (IDH) is the most mutated metabolic gene in
human cancer. Mutations in this gene have been identified in a high percentage of gliomas …

Simple Summary Preclinical models are essential for the advancement of our understanding
of glioma biology and the development of novel therapeutics. Much of our progress in the …